|
|
|
|
 |
|  =Subscribers Only |
Get Four
|
|
 OCTOBER 11, 2001 Stents Make Investors' Hearts Beat Faster Successful tests of a drug-coated device that keeps clogged arteries open have propelled Johnson & Johnson to a handy lead over rivals  AUGUST 16, 2001 The Personalized Future of Medicine Drug treatments tailored to match individual patients' genes sound like science fiction -- except, in a limited way, they're already here JULY 12, 2001 Artistic Allusions -- or Delusions? -- at Human Genome Sciences Biotech pioneer William Haseltine uses his passion for art to explain what his genomics company does -- in a most unusual way JUNE 28, 2001 Gene Therapy Is on the Mend Rocked two years ago by a tragic death, the science is rebounding, thanks to strict experimental protocols. Long-term investors take note JUNE 21, 2001 Rosetta Inpharmatics: Translating Genes into Profits? Merck's acquisition of the genomics pioneer may give the No. 2 pharmaceutical company a huge advantage in developing new drugs JUNE 15, 2001 For Now, Diabetics Must Keep on Waiting to Inhale Insulin administered via an oral spray promises to free millions from the pain and peril of daily shots -- if safety concerns don't delay its debut JUNE 7, 2001 Proteomics: Beyond the Genome IBM and MDS are building a giant database devoted to protein interactions. Here's a chat with the developer, who sees it as the next big thing in medicine JUNE 1, 2001 Surgery That Doesn't Draw on the Blood Bank With AIDS and hepatitis fears rising, more hospitals are adopting and advancing bloodless techniques MAY 21, 2001 Drugmakers Need to Break Their Blockbuster Addiction The industry would be wise to diversfy its revenue streams. Otherwise, the pressures on it to ease up on prices will only intensify MAY 3, 2001 What Women Want Those with sexual dysfunction want drugs to increase their sex drive. And several drugmakers are racing to accommodate them APRIL 26, 2001 So Far, Millennium Is Missing Its Milestones The biotech hotshot's sluggish pipeline may stop it from getting its promised drugs to market and meeting its lofty financial goals APRIL 19, 2001 Mortal Combat for the Painkillers It's Merck's Vioxx vs. Pharmacia's Celebrex, and they've been about evenly matched. However, Merck may soon gain an edge APRIL 12, 2001 Is It Time for the Mating Dance Yet? With a consolidation wave in view, cash-rich biotechs are taking out their wallets APRIL 5, 2001 OSI's Plunge May Disguise Its Promise The drugmaker's potentially hot cancer drug, cash hoard, and good partnerships offset a fallen stock that once surged 909% MARCH 22, 2001 AHP's Long, Hard Road to Wellness With the fen-phen fiasco finally fading, this embattled drugmaker is looking foward again, despite the many doubters MARCH 15, 2001 The Vertex Vortex: Drug Development at Hyperspeed? Vertex Pharmaceuticals says it can quickly spot winning drugs. Many analysts think it may have a good shot at fulfilling its promise MARCH 8, 2001 Striking Out Against Strokes An effective treatment with huge potential exists, but it's no blockbuster because few patients get the drug in time MARCH 1, 2001 The Fog Shrouding Schering-Plough Quality-control problems with the FDA have thrown its near-term prospects into doubt. It could even become a takeover play FEBRUARY 22, 2001 Human Drugs from Goat's Milk? Genzyme Transgenics is betting the farm that genetically altered ruminants can manufacture medicinal proteins FEBRUARY 15, 2001 Preventing HIV from Breaking and Entering Trimeris' new drugs appear to lock the virus out of cells. If so, they'd be a big improvement over current therapies FEBRUARY 8, 2001 Immunex' Supply-Side Cliffhanger Its Enbrel arthritis treatment is a runaway blockbuster. But if it can't keep up with demand, rivals could take advantage FEBRUARY 1, 2001 Generic Biotech Drugs? Don't Count Them Out Makers of generics want to compete, and consumers want lower prices, so the biotechs' patent dominance may be short-lived JANUARY 25, 2001 The Quest for Cancer Killers Novartis Oncology's David Parkinson talks about how labs worldwide are developing agents that can really cause excitement JANUARY 11, 2001 Is Praecis' Prostate Drug Good Enough? Despite strong clinical data and a marketing deal with Amgen, some analysts and doctors question Abarelix' potential View Previous Page | The Biotech Beat Archive | |
|
Copyright Bloomberg L.P.